AngioDynamics stock maintains Buy rating at H.C. Wainwright after Q4 beat

Investing.com - H.C. Wainwright has reiterated its Buy rating and $16.00 price target on AngioDynamics (NASDAQ:ANGO) following the company’s fiscal fourth-quarter 2025 earnings report. According to InvestingPro data, the company maintains a FAIR financial health score, with the notable strength of holding more cash than debt on its balance sheet.

The medical device company reported net sales of $80.2 million for the quarter ending May 31, exceeding analyst projections of $74.5 million and representing 12.7% pro forma year-over-year growth. Med Tech net sales grew 22.0% to $35.8 million, while Med Device net sales increased 6.2% to $44.4 million.

AngioDynamics posted a quarterly net loss of $6.1 million, or $0.15 per share, which was smaller than the expected loss of $9.3 million. The company’s product lines showed strong performance, with Auryon sales up 19.7%, AngioVac sales increasing 39.5%, and AlphaVac sales growing 60.8%.

For the full fiscal year 2025, AngioDynamics reported net sales of $292.7 million, representing 8.1% pro forma year-over-year growth. The company recorded a net loss of $34.0 million, or $0.83 per share, with adjusted EBITDA of $13.1 million.

Looking ahead to fiscal year 2026, management provided guidance for net sales between $305-310 million, with Med Tech sales expected to grow 12-15% year-over-year while Med Device sales remain flat. The company anticipates a gross margin of 53.5-55.5%, adjusted EBITDA of $3.0-8.0 million, and expects to be free cash flow positive for the year. Discover more insights with InvestingPro, which offers 8 additional key tips about ANGO and a comprehensive Pro Research Report, helping investors make informed decisions with expert analysis and detailed metrics.

In other recent news, AngioDynamics reported its fourth-quarter fiscal 2025 results, surpassing earnings expectations with an EPS of -$0.03 against the forecasted -$0.12. The company’s revenue reached $80.2 million, exceeding expectations of $74.27 million and marking a 12.7% year-over-year growth. This performance was driven by the MedTech segment, which saw a 22% increase, contributing $35.8 million to the total revenue. Meanwhile, Canaccord Genuity raised its price target for AngioDynamics to $17.00 from $15.00, maintaining a Buy rating due to the company’s strong quarterly performance across multiple metrics. Additionally, Lake Street Capital Markets initiated coverage on AngioDynamics with a Buy rating, highlighting the company’s strategic realignment and MedTech growth profile. For fiscal year 2026, AngioDynamics projects net sales between $305 million and $310 million, with MedTech revenue expected to grow by 12-15%. The company aims to become cash flow positive in FY26, despite potential tariff impacts. These developments reflect AngioDynamics’ ongoing strategic transformation and commitment to expanding its market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.